Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia

Proteome Science

Volumn 9, Issue , 2011, Pages

  Májek, Pavel ^a   Reicheltová, Zuzana ^a   Suttnar, Jiří ^a   Čermák, Jaroslav ^a   Dyr, Jan E ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Dysplasia; Myelodysplastic syndrome; Proteome; Refractory cytopenia

Indexed keywords

COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; ENDOREPELLIN; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 80053508377     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-64     Document Type: Article

References (31)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302. 10.1182/blood-2002-04-1199, 12239137.
2. Vasikova A, Belickova M, Budinska E, Cermak J. A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome. Leuk Res 2010, 34:1566-1572. 10.1016/j.leukres.2010.02.021, 20303173.
3. Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, Cermak J. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011, 4:1. 10.1186/1756-8722-4-1, 3024999, 21211043.
4. Vasikova A, Budinska E, Belickova M, Cermak J, Bruchova H. Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome. Neoplasma 2009, 56:335-342. 10.4149/neo_2009_04_335, 19469654.
5. Kracmarova A, Cermak J, Brdicka R, Bruchova H. High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome. Leuk Lymphoma 2008, 49:1297-1305. 10.1080/10428190802129918, 18604718.
6. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011, 19:313-319. 10.1038/ejhg.2010.209, 21150891.
7. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 2007, 104:1307-1312. 10.1073/pnas.0610330104, 1783137, 17220270.
8. Májek P, Reicheltová Z, Suttnar J, Malý M, Oravec M, Pečánková K, Dyr JE. Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. J Transl Med 2011, 9:84. 10.1186/1479-5876-9-84, 21631938.
9. Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG. Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). Leukemia 2010, 24:1875-1884. 10.1038/leu.2010.182, 20739954.
10. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res 2009, 15:3820-3826. 10.1158/1078-0432.CCR-08-3034, 19458051.
11. Májek P, Reicheltová Z, Stikarová J, Suttnar J, Sobotková A, Dyr JE. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 2010, 8:56. 2996359, 21073729.
12. Riedel T, Suttnar J, Brynda E, Houska M, Medved L, Dyr JE. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood 2011, 117:1700-1706. 10.1182/blood-2010-08-300301, 21106983.
13. Chang JW, Kang UB, Kim DH, Yi JK, Lee JW, Noh DY, Lee C, Yu MH. Identification of circulating endorepellin LG3 fragment: Potential use as a serological biomarker for breast cancer. Proteomics Clin Appl 2008, 2:23-32. 10.1002/prca.200780049, 21136776.
14. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9:1225-1235. 10.1038/ni.1655, 2678913, 18820683.
15. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
16. Torrealba JR, Samaniego M, Pascual J, Becker Y, Pirsch J, Sollinger H, Odorico J. C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation 2008, 86:1849-1856. 10.1097/TP.0b013e3181902319, 19104433.
17. David-Neto E, Prado E, Beutel A, Ventura CG, Siqueira SA, Hung J, Lemos FB, de Souza NA, Nahas WC, Ianhez LE, David DR. C4d-positive chronic rejection: a frequent entity with a poor outcome. Transplantation 2007, 84:1391-1398. 10.1097/01.tp.0000288807.52520.5e, 18091514.
18. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker?. Nephrol Dial Transplant 2003, 18:2232-2239. 10.1093/ndt/gfg304, 14551348.
19. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999, 20:576-582. 10.1016/S0167-5699(99)01537-6, 10562709.
20. Moretti S, Lanza F, Spisani S, Latorraca A, Rigolin GM, Giuliani AL, Castoldi GL, Traniello S. Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement receptors, functional activities and disease status. Leuk Lymphoma 1994, 13:471-477. 10.3109/10428199409049637, 8069192.
21. Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 2010, 8:58. 10.1186/1477-5956-8-58, 2998473, 21083881.
22. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284. 1323259, 16395409.
23. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW, Weinberger SR. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005, 115:783-789. 10.1002/ijc.20928, 15704152.
24. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890. 10.1158/0008-5472.CAN-04-0746, 15313933.
25. Mohamed E, Abdul-Rahman PS, Doustjalali SR, Chen Y, Lim BK, Omar SZ, Bustam AZ, Singh VA, Mohd-Taib NA, Yip CH, Hashim OH. Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis 2008, 29:2645-2650. 10.1002/elps.200700828, 18494030.
26. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, Iozzo RV. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 2006, 98:1634-1646. 10.1093/jnci/djj441, 17105986.
27. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Höök M, Reed CC, Iozzo RV. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 2004, 166:97-109. 10.1083/jcb.200401150, 2172143, 15240572.
28. Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS, Iozzo RV. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 2005, 280:7080-7087. 10.1074/jbc.M409841200, 15591058.
29. Vuadens F, Benay C, Crettaz D, Gallot D, Sapin V, Schneider P, Bienvenut WV, Lémery D, Quadroni M, Dastugue B, Tissot JD. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics 2003, 3:1521-1525. 10.1002/pmic.200300455, 12923777.
30. Oda O, Shinzato T, Ohbayashi K, Takai I, Kunimatsu M, Maeda K, Yamanaka N. Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin Chim Acta 1996, 255:119-132. 10.1016/0009-8981(96)06395-4, 8937755.
31. Ignjatovic V, Lai C, Summerhayes R, Mathesius U, Tawfilis S, Perugini MA, Monagle P. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS One 2011, 6:e17213. 10.1371/journal.pone.0017213, 3041803, 21365000.